02747nam 2200625 a 450 991043782710332120251205184136.01-283-62448-697866139369361-4614-4815-810.1007/978-1-4614-4815-0(CKB)2670000000246545(EBL)994590(OCoLC)811139863(SSID)ssj0000767095(PQKBManifestationID)11429475(PQKBTitleCode)TC0000767095(PQKBWorkID)10739886(PQKB)11209362(DE-He213)978-1-4614-4815-0(MiAaPQ)EBC994590(PPN)16830127X(EXLCZ)99267000000024654520120814d2013 uy 0engur|n|---|||||txtccrMicrodialysis in drug development /Markus Muller, editor1st ed. 2013.New York Springer20131 online resource (341 p.)AAPS advances in the pharmaceutical sciences series,2210-7371Description based upon print version of record.1-4899-9621-4 1-4614-4814-X Includes bibliographical references and index.pt. 1. General aspects -- pt. 2. Specific topics.In vivo target site concentrations are probably the most important determinant of drug effects. Traditionally, linking drug concentrations to drug effects has been accomplished by modelling blood-derived data, mostly because a direct quantification of tissue concentrations has been beyond technical reach. Today, a direct measurement of target site concentrations is possible by employing microdialysis or complementary approaches such as imaging technologies. Microdialysis, initially conceived in the 1970ies, has become a standard tool in drug development. This comprehensive overview of current microdialysis technology covers general and disease-specific aspects of microdialysis by international experts in the field. It provides useful information for colleagues in academia and industry who are interested PK-PD aspects of drug development.AAPS Advances in the Pharmaceutical Sciences Series,2210-7371 ;4Drug developmentBrain microdialysisDrug development.Brain microdialysis.615/.19616.8/04754Müller Markus1967 August 23-1859830MiAaPQMiAaPQMiAaPQBOOK9910437827103321Microdialysis in drug development4464060UNINA